P46374 10th Annual Biosimilars Asia
Download Brochure Request

Register your interest


Register your interest


10th Annual Biosimilars Asia

15 – 16 May 2019, Shanghai Marriott Hotel Parkview, China

Register Your Interest Download Brochure



China steadfastly continues to work regulations on biosimilars to help make the market easier to breakthrough, and the recent Priority Review legislation is a case in point. As the industry continues to evaluate cost, risk and incentives for Biosimilar development, new developments to promote R&D and adjustments to approval pathways are designed to help manufacturing and commercialization of biosimilars.

IBC’s 10th Biosimilars Asia is one of 5 conferences part of the 5th Biopharma Development and Production Week in China. It will address the business case, approvals, future manufacturing strategies  and commercialisation, in a market that is expected to be worth $20 billion globally by 2022.

Key Highlights

  • CFDAs priority review policy and impact on biosimilars
  • The current clinical trial landscape for new biosimilars, and expected pipelines
  • The oncology Biosimilars market
  • Future manufacturing strategies
  • Proving similarity
  • Managing product variations
  • Innovation and technology breakthroughs for biosimilar development
  • Pricing and Promotion strategies
  • Commercialisation strategies for the China biosimilars market
  • Anticipating investment across the value chain for successful biosimilar commercialisation

Part of

5th Annual BioPharma Development and Production Week »

With demonstrated success year on year, IBCs BDP Week in China enjoys unparalleled industry support. Known for generating knowledge, creating business opportunities, and bringing innovative ideas to the table, the BDP Week is now more impactful than ever with 5 high level conferences, learning seminars, focused trade show and business matching to boot.

Co located conferences

The BDP Party!

When: Wednesday, 15 May 2019 at 6.30pm
Where: Shanghai City Bistro, Level 1, Shanghai Marriott Parkview Hotel
Cost: CNY 350 / USD 50 net (inclusive of buffet dinner and free flow wine / beer)

  • Registration is not limited to conference participants and we encourage all who are in the BDP industry to attend.
  • Dinner will only proceed when we have reached 100 participants.
  • Payment is only required when the dinner is confirmed.
  • Participants list for the dinner will be made available online once the registration reaches 100 participants.

CNY Pricing

  • 2 Day Conference: CNY 6,500
  • Group of 2 or more delegates: CNY 5,000
  • Group of 4 or more delegates: CNY 4,500
  • Pre Conference Workshop: CNY 1,000
  • Gala Dinner: CNY 350


Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

Exhibition Floorplan >>


Judith Li

Partner, Lilly Asia Ventures, Hong Kong

Feng Tao

Founding Partner, Biotrack Capital, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Peter Luo

CEO, Adagene Pharma, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

Co-Founder and Executive Chairman, TRANSCENTA HOLDING, China

Dr Wu Youling

Chief Executive Officer, ZheJiang Teruisi Biopharmaceutical, China

Dr. Manfred Weiler

Senior Vice President, Medical & Scientific Strategy, Syneos Health, UK

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Dr Zou Linglong

Executive Director, Head of Bioanalytics, Shanghai Henlius Biotech, China

Frank Ye

Senior Vice President, Technical Operations, Hangzhou JUST Biotherapeutics, China

Dr Dennis Lin

Supervisor, Upstream Process Development, Mycenax Biotech Inc, Taiwan

Asif Mahmood

Disease Area Cluster Lead, Pfizer, USA

Dr Peter Pang

General Manager, XiKang (Wuhan) Biopharmaceutical Co.Ltd., EVP, Corporate Head of Regulatory Affairs, JHL Biotech Inc, China

Sumimasa Nagai

Deputy Director of the Translational Research Centre / Clinical Expert Advisor at the Office of New Drug V (Oncology) and Companion Diagnostics Working Group, University of Tokyo Hospital / Pharmaceuticals and Medical Devices Agency, Japan

Dr Jiang Weidong

Vice President and Chief Scientific Officer, Shanghai Henlius Biotech, China

Wang Yongzhong

President of Pharmaceuticals, Executive Vice President, Simcere Pharmaceutical Group, China

Dr Jerry Dong

Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr. Jerry Yang

Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics, China

when & where

15 - 16 May 2019

Shanghai Marriott Hotel Parkview
333 Guang Zhong Road West, Jing’an District
Shanghai, 200072 China
Phone:+86 21 3669 8888
Fax:+86 21 3669 8668

Cartrina Wang 王洁琼 | Senior Sales Manager-EBC
T: 86 21 3669 8666 | M:13585605981



Still have a question?

Speaking Opportunities
Wong Shi Hui
+65-6508 2479


Sponsorship Opportunities
Yvonne Leong
+65 6508 2489


Media & Association Partnership Opportunities
Tham Ruohyi
+65 6508 2463





Conference Partner Conference Partner


IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more

We are changing our brand to Informa Connect
Learn More